Our life-changing research relies on a range of sophisticated technologies. We are harnessing these technologies to personalise healthcare and help people live healthier for longer.
The 9.4T animal magnetic resonance imaging system is optimised for high-resolution sample imaging.
Our Mission is to reduce death and disability from cardiovascular disease, diabetes and related conditions through research, education and health care delivery.
The Biomarker Discovery Platform provides infrastructure for the detection and quantification of biomarkers, such as proteins, peptides and nucleotides, in any biological fluids and samples.
Magnetic Particle Imaging (MPI) is a new non-invasive imaging method that detects iron oxide nanoparticles to produce 2D and 3D images. MPI imaging is more sensitive and significantly faster than MRI and PET imaging.
The Metabolomics (lipidomic) Profiling Facility uses state-of-the-art tandem mass spectrometry to obtain metabolic profiles (primarily lipids) from cell and animal models.
The Mediso NanoPET/CT is a small animal preclinical scanner suitable for a wide variety of radioactive tracer imaging and computer tomography (CT).
The Preclinical Cardiology Microsurgery and Imaging Platform team are leaders in clinical assessments of animal models for trials of new medicines.
The Proteomics Research Platform develops and applies advanced proteomics methods to further our understanding of cardiac disease, pathways, targets, and drug effects.
The Single-Cell Omics Platform applies single-cell omic approaches to understand complex tissues in context of development and disease.
With the rising number of Australians affected by diabetes, heart disease and stroke, the need for research is more critical than ever.Find out more